# NCT04172675 (NCT04172675)

> A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04172675
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Urinary Bladder Neoplasms
- Interventions: Erdafitinib; Investigator Choice (Gemcitabine); Investigator Choice (Mitomycin C)
- Enrollment: 107
- Primary outcome: Cohort 1: Recurrence-Free Survival (RFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct04172675